Your Partner in Life Sciences Growth
501 Ventures is focused on accelerating the development of transformative patient therapies by leveraging extensive industry expertise, delivering funding and providing services vital for streamlined and successful drug development.
Services
Our firm specializes in supporting life sciences companies at critical growth and transition points. Through a combination of strategic advisory services and investment support, 501 Ventures serves clients through critical milestones at every stage of company development.
Advisory Services
We provide strategic and scientific advisory offerings to help companies navigate a complex partnering and M&A environment.
Investment Support
Targeted average placements ranging from
$10 – $25M.
Therapeutic Focus Areas
Cardiometabolic
- Obesity
- Diabetes
- Cardiovascular Diseases
Immunology & Inflammation
- Autoimmune Diseases
- Osteoarthritis
Meet the Founders
Enrique Conterno
Executive Chairman
An experienced board member and CEO with extensive experience in the field of Cardiometabolism.
Enrique led Lilly’s reestablishment of its leadership position in cardiometabolism as President of the business for over 10 years, overseeing development and/or commercialization of transformational products, including Trulicity, Jardiance, Mounjaro/Zepbound and Orforglipron.
Currently a Board Member at: 
Meg Powell
CEO & Co-founder
A seasoned executive turned serial entrepreneur & industry expert.
Meg’s expertise spans organizational leadership, business creation, commercialization strategy, fundraising, M&A/complex transactions, product launch, marketing and branding, and organizational transformation. She has successfully created and exited 2 startups each returning ~10x MOIC.
Currently a Board Member at: 
501 Ventures Offices
